Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.

Authors:
Address: College of Pharmacy, Washington State University, Spokane, WA, USA. jneumiller@wsu.edu
Journal:

Publication:

abstract

OBJECTIVE:

To review the Pharmacology, pharmacokinetics, and clinical efficacy and safety of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor recently approved in the US for use as a treatment for type 2 diabetes mellitus.

DATA SOURCES:

English-language articles in the PubMed database to October 2011 (selected using the search terms linagliptin, alogliptin, sitagliptin, saxagliptin, vildagliptin, and pharmacokinetics, pharmacodynamics, or diabetes) were identified for review. Reference lists from identified articles were reviewed for additional references of interest. Abstracts published at relevant meetings were also evaluated, and information was obtained from the manufacturer.

STUDY SELECTION AND DATA EXTRACTION:

Publications reporting the pharmacology, pharmacokinetics, and clinical efficacy and safety of linagliptin were reviewed.

DATA SYNTHESIS:

Linagliptin therapy results in clinically meaningful reductions in hemoglobin A(1c), as well as fasting and postprandial plasma glucose levels in patients with type 2 diabetes mellitus. It contrasts with other agents in its class by not requiring dosage adjustment in patients with renal or hepatic impairment. Oral doses of linagliptin 5 mg once daily have been shown to be clinically effective, well tolerated, and weight-neutral. An increased rate of hypoglycemia when linagliptin was used in combination with an insulin secretagogue compared to placebo was noted in clinical trials.

CONCLUSIONS:

Linagliptin provides an additional therapeutic option for type 2 diabetes mellitus and, in contrast to other agents in the DPP-4 class, can be used without dose adjustment in patients with any degree of declining renal function.

Related Articles
Review of linagliptin for the treatment of type 2 diabetes mellitus.
Clin Ther. 2012
Review of linagliptin for the treatment of type 2 diabetes mellitus.
Neumiller JJ, Setter SM. Clin Ther. 2012 May; 34(5):993-1005. Epub 2012 Mar 21.
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Clin Ther. 2011
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA. Clin Ther. 2011 Jul; 33(7):973-89. Epub 2011 Jul 2.
Review Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Clin Ther. 2007
Review Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Zerilli T, Pyon EY. Clin Ther. 2007 Dec; 29(12):2614-34.
Review Insulin glargine: a systematic review of a long-acting insulin analogue.
Clin Ther. 2003
Review Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F, Carabino JM, Vergara CM. Clin Ther. 2003 Jun; 25(6):1541-77, discussion 1539-40.
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Clin Ther. 2010
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA. Clin Ther. 2010 Jun; 32(6):1188-204.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.